At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 256 enrolled
Drug / intervention
SB206 4% +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Multi-Center, Randomized, Double-Blind, Vehicle-Controlled Ascending Dose Study of SB206 in Subjects With Molluscum Contagiosum
In Brief
A Phase 2 clinical trial evaluating SB206 4%, SB206 8%, and 2 other interventions for Molluscum Contagiosum. Completed, enrolled 256 participants across 18 sites.
Detailed Summary
This is a phase 2 multi-center, randomized, double-blind, vehicle-controlled ascending dose study to be conducted in non-immunocompromised subjects with molluscum contagiosum.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMolluscum Contagiosum
CountriesUnited States
CollaboratorsPremier Research
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartJan 2018
First PostedFeb 2018
Primary CompletionNov 2018
TodayJul 2026
First PostedFeb 19, 2018
Enrollment StartJan 24, 2018
Primary CompletionNov 3, 2018
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 8.4 years ago
Interventions
SB206 4%drug
Twice daily
SB206 8%drug
Twice daily
SB206 12%drug
Once or twice daily
Placebodrug
Once or twice daily